Junaid Ishaq Tantray

Mr. Junaid Ishaq Tantray

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
JTJunaid Ishaq Tantray
Junaid Ishaq Tantray
APAkhilesh Patel
Akhilesh Patel
HPHiba Parveen
Hiba Parveen
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
JPJigna Bhupendra Prajapati
Jigna Bhupendra Prajapati

1 December 2024 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
JTJunaid Ishaq Tantray
Junaid Ishaq Tantray
APAkhilesh Patel
Akhilesh Patel
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
SKSourabh Kosey
Sourabh Kosey
SBSankha Bhattacharya
Sankha Bhattacharya
: Ovarian cancer poses a formidable health challenge for women globally, necessitating innovative therapeutic approaches. This review provides a succinct summary of the current research status on lipid-based nanocarriers in the context of ovarian cancer treatment. Lipid-based nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), offer a promising solution for delivering anticancer drugs with enhanced therapeutic effectiveness and reduced adverse effects. Their versatility in transporting both hydrophobic and hydrophilic medications makes them well-suited for a diverse range of anticancer drugs. Active targeting techniques like ligand-conjugation and surface modifications have been used to reduce off-target effects and achieve tumour-specific medication delivery. The study explores formulation techniques and adjustments meant to enhance drug stability and encapsulation in these nanocarriers. Encouraging results from clinical trials and preclinical investigations underscore the promise of lipid-based nanocarriers in ovarian cancer treatment, providing optimism for improved patient outcomes. Notwithstanding these advancements, challenges related to clearance, long-term stability, and scalable manufacturing persist. Successfully translating lipidbased nanocarriers into clinical practice requires addressing these hurdles. To sum up, lipidbased nanocarriers are a viable strategy to improve the effectiveness of therapy for ovarian cancer. With their more focused medication administration and lower systemic toxicity, they may completely change the way ovarian cancer is treated and increase patient survival rates. Lipidbased nanocarriers need to be further researched and developed to become a therapeutically viable treatment for ovarian cancer.

11 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
HJHézio Jadir Fernandes Jr
Hézio Jadir Fernandes Jr
EAERISVALDO AMARANTE DE ARAÚJO AMARANTE
ERISVALDO AMARANTE DE ARAÚJO AMARANTE
JJJosé Antônio Machado Junior
José Antônio Machado Junior
FMFábio Marinho Motta
Fábio Marinho Motta
GGGabriela Ferrazzano Guarize
Gabriela Ferrazzano Guarize
FMFrancisco Sandro Menezes-Rodrigues
Francisco Sandro Menezes-Rodrigues
Background/Objectives: Treatment of patients with myocardial ischemic diseases crucially involves cardiac reperfusion (CR). However, oxidative stress and tissue lesions caused by CR may also lead to lethal complications, such as arrythmias and vasoplegic syndrome (VS). Although methylene blue (MB) has long been used to treat VS due to cardiac ischemia and reperfusion (CIR) and/or surgery because of its vascular effects, MB’s effects on the heart are unclear. Therefore, we investigated the potential cardioprotective or arrhythmogenic effects of MB in an animal model of CIR. To this end, 12–16-week-old male Wistar rats were divided into four experimental groups: (a) rats subjected to SHAM surgery with no ischemia; (b) rats subjected to CIR and treated with a vehicle (SS + CIR); and (c) rats subjected to CIR and treated with 2 mg/kg i.v. MB before ischemia (MB + ISQ) or (d) after ischemia but before reperfusion (ISQ + MB). An ECG analysis was used to evaluate the incidence of ventricular arrhythmias (VAs), atrioventricular blocks (AVBs), and lethality (LET) resulting from CIR. After CIR, rat hearts were removed for histopathological analysis and lipid hydroperoxide (LH) measurements. Results: The incidence of VA, AVB, and LET was significantly increased in the MB + ISQ group (VA = 100%; AVB = 100%; LET = 100%) but significantly reduced in the ISQ + MB group (VA = 42.8%; AVB = 28.5%; LET = 21.4%) compared with the SS + CIR group (VA = 85.7%; AVB = 71.4%; LET = 64.2%). LH concentration was significantly reduced in both MB-treated groups, but myocardial injuries were increased only in the MB + ISQ group when compared with the SS + CIR group. Conclusions: These results indicate that MB produces a biphasic effect on CIR, with cardiotoxic effects when administered before cardiac ischemia and cardioprotective effects when administered after ischemia but before cardiac reperfusion.

28 January 2023 in Health Sciences Review
Verified
Journal Article
Open access
MBMehvish Bhat
Mehvish Bhat
MZMohammad Zaid
Mohammad Zaid
Shivam SinghShivam Singh
Shivam Singh
KGKartik Gill
Kartik Gill
JTJunaid Ishaq Tantray
Junaid Ishaq Tantray
ASAshish Kumar Sharma
Ashish Kumar Sharma

1 January 2026 in Acta Cirurgica Brasileira
Verified
Journal Article
Open access
JTJunaid Ishaq Tantray
Junaid Ishaq Tantray
FMFrancisco Sandro Menezes-Rodrigues
Francisco Sandro Menezes-Rodrigues
JPJosé Mario Podanosque
José Mario Podanosque
FTFernando Sabia Tallo
Fernando Sabia Tallo
ACAfonso Caricati-Neto
Afonso Caricati-Neto
BBBolatkan Arlan Beibituly
Bolatkan Arlan Beibituly
Purpose: Hypothesis centered on the idea that ranolazine could induce responses similar to ischemic preconditioning, involving nitric oxide, adenosine, bradykinin, and adenosine triphosphate (ATP)-dependent potassium channels. Methods: Ischemia-reperfusion injury was established using Langendroff technique. Thirty-minute ischemia and 120-minute reperfusion to coronary artery to isolated heart were model of myocardial infarction. There were studied the following groups: control (ischemia-reperfusion), ischemic preconditioning, ranolazine (10 µmol/L), ranolazine + L-NAME (30 µmol/L) and ranolazine + aminoguanidine (30 µmol/L), ranolazine + theophylline (50 µmol/L), ranolazine + aminophylline (50 µmol/L), ranolazine + icatibantl (100 µmol/L), ranolazine + bromelain (250 µmol/L), ranolazine + 5-hydroxydecanoate (30 µmol/L), and ranolazine + glimepiride (50 µmol/L) in perfusate. Results: Ranolazine and ischemic preconditioning groups demonstrated cardioprotective effects by reducing infarct size, as well as levels of lactate dehydrogenase (LDH), creatine phosphokinase myoglobin (CK-MB), and troponin I and cardiac parameters like left ventricular developed pressure (LVDP) and left ventricular maximum rate of contraction (dP/dTmax). Maximum rate of relaxation (dP/dTmin) was improved. Conversely, treatments with L-NAME, aminoguanidine, theophylline, aminophylline, icatibant, bromelain, 5-hydroxydecanoate, and glimepiride increased infarct size, LDH, CK-MB, and troponin I levels, and cardiac parameters like LVDP, dP/dTmax, and dP/dTmin were depressed. This data provides evidence that ranolazine employs nitric oxide, adenosine, bradykinin, and ATP-dependent potassium channels as secondary messengers in cardioprotection. Conclusion: ranolazine can be a pharmacological alternative to surgical ischemic preconditioning utilized prior to interventional procedures like coronary artery bypass graft surgery and heart transplantation, offering improved patient compliance.

7 July 2025 in Health Sciences Review
Verified
Journal Article
Open access
AKAman Kumar
Aman Kumar
JTJunaid Ishaq Tantray
Junaid Ishaq Tantray
SKSourabh Kosey
Sourabh Kosey
CDChingtham Henthoibi Devi
Chingtham Henthoibi Devi
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati